Histolix patented technology provides a new intrinsically digital slide-free histopathology solution that is deployable in both pathology labs as well as clinician-focused point-of-care settings, eliminating delays from current pathology workflow. Supported by millions in grant and private funding with three years of development completed, Histolix has licensed its patented “direct read” technology from University of…
Location: United States, California, Sacramento
Employees: 11-50
Total raised: $3.2M
Founded date: 2019
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.06.2023 | Grant | $3.2M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 30.06.2023 | Histolix Receives Additional $3.2M Grant | Histolix, a Sacramento, CA-based developer of direct-to-digital read pathology solutions, received a... | finsmes.co... |
| 28.06.2023 | Histolix Team Receives Additional $3.2 Million Funding for R... | We believe Histolix could reduce or eliminate breast lumpectomy re-excision procedures resulting fro... | prweb.com/... |
| 05.04.2022 | Histolix Digital FIBI Equivalency Study Results in No Major ... | I was pleased to see Histolix concordance fall within and be even better than the FDA guidelines for... | prweb.com/... |
| 18.10.2021 | Histolix Launches Direct-to-Digital Pathology Read Diagnosti... | The Histolix technology heralds a radically new approach to the preparation of the images required b... | prweb.com/... |